Cytovale has developed the IntelliSep test, an FDA-cleared diagnostic tool that analyzes the biomechanical properties of white blood cells from a standard blood draw to assess a patient's risk of sepsis within 8 minutes. This rapid detection addresses the critical challenge of timely diagnosis in sepsis, a condition that increases mortality by 8% for every hour treatment is delayed.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+3Founders
Product
Problem
Sepsis, a life-threatening condition, requires rapid diagnosis and treatment, but current methods lack the sensitivity for early detection. Delayed treatment increases mortality by 8% for every hour of delay. Clinicians need a more effective tool to quickly identify patients at risk.
Solution
Cytovale's IntelliSep test is an FDA-cleared in vitro diagnostic tool that assesses a patient's risk of sepsis by analyzing the biomechanical properties of white blood cells from a standard blood draw. The test provides results in approximately 8 minutes, enabling faster care and optimized patient outcomes. IntelliSep measures the immune response to infection, providing a probability of sepsis occurring within 3 days of testing. This rapid risk stratification helps emergency department providers make informed decisions and triage patients to the appropriate care pathway.
Target Audience
The primary users are emergency department physicians, nurses, and laboratorians who need a rapid and accurate tool for sepsis detection, as well as hospital administrators seeking to improve patient outcomes and operational efficiencies.
Features
- Analyzes the biomechanical properties of white blood cells to assess immune activation
- Provides results in approximately 8 minutes
- Risk-stratifies patients based on their probability of having sepsis within 3 days post-testing
- Offers a highly sensitive measure for identifying sepsis